News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Thierry Hercend joins Covagen's Scientific Advisory Board


4/7/2010 2:41:42 PM

Zurich, Switzerland, April 7, 2010 Covagen, an ETH Zurich spin-off company pioneering the development of a novel class of protein therapeutics (Fynomers), announced today that it has further strengthened its Scientific Advisory Board (SAB), which will be expanded by the addition of Dr. Thierry Hercend.

Dr. Thierry Hercend (MD, Ph.D.) has over 30 years of both academic and pharmaceutical experience in various therapeutic areas including oncology and inflammatory diseases. Since 2006, Dr. Thierry Hercend has been a Venture Partner at Edmond de Rothschild Investment Partners (EdRIP). He is the Chairman of the Supervisory Board of the biotechnology companies Cytomics Pharmaceuticals (Orsay, France) and Genticel (Innopole, France), and a member of the Scientific Advisory Board of Noxxon (Berlin, Germany). From 2002 until 2005, Dr. Hercend was Vice President in charge of the oncology therapeutic area at Aventis. From 1998 to 2002, he was Vice President of Research, Europe, at Vertex Pharmaceuticals (Cambridge, US). Previously, Dr. Hercend was Head of Research and Development for the Laboratory of Plasma Fractionation and Biotechnology (LFB) and was in various executive R&D positions with Roussel-Uclaf (Romainville, France). Prior to joining the pharmaceutical industry, Dr. Hercend was Head of the Hemato-Immunology laboratories of the Gustave Roussy Cancer Institute (Villejuif, France), Director of the Inserm unit U333 dedicated to tumor immunology and a Professor of Immunology at the Medical Faculty of Paris XI University. He has authored more than 120 publications in oncology, auto-immune diseases and transplantation.

“We are very proud that we were able to attract Dr. Hercend to our Scientific Advisory Board and are looking forward to working with him”, said Dr. Julian Bertschinger, CEO of Covagen. “He will be very valuable for the further development of Covagen.”

About Covagen:

Covagen develops next generation protein drugs for the treatment of inflammatory diseases and cancer by using its proprietary protein engineering technology, which has been developed at ETH Zurich (Switzerland). Covagen's innovative platform comprises the recently developed Covalent DNA Display technology and a novel single domain protein scaffold, which - in analogy to antibodies - can be engineered to yield high affinity binding proteins called Fynomers that can be used for therapeutic applications. In addition, the modular structure of Covagen's Fynomers and its favorable biophysical properties potentially allow for treatment modalities that are difficult or impossible to be exploited with antibodies. For more information, please visit http://www.covagen.com.

Read at BioSpace.com


comments powered by Disqus
Covagen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES